Bachem Holding AG engages in the provision of peptides and oligonucleotides. The company is headquartered in Bubendorf, Basel-Landschaft and currently employs 2,511 full-time employees. The company went IPO on 2001-06-29. The firm focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The firm markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.
根據最新的財務報表(Form-10K),Bachem Holding AG 的總資產為 $2,108,淨利潤為 $148
BCHMF 的關鍵財務比率是什麼?
Bachem Holding AG 的流動比率為 3.24,淨利潤率為 21.29,每股銷售為 $9.27。
Bachem Holding AG 的收入按細分市場或地理位置如何劃分?
Bachem Holding AG 最大收入來源為 Commercial Active Pharmaceutical Ingredients,在最近的收益報告中收入為 327,002,000。就地區而言,United States 是 Bachem Holding AG 的主要市場,收入為 183,800,000。